Agent Bricks automatically optimizes AI agents on customers' unique data to deliver cost-efficient, trustworthy agents SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- Data + AI Summit -- Databricks ...

AstraZeneca got a closer look at CSPC’s drug research capabilities last year. Last October, the pharma giant paid $100 million up front to license a preclinical CSPC drug in development for the ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He’d like it to be higher.

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on limiting prescription drug prices goes against a federal program.

On ASCO Day 3, AstraZeneca is dominant (again), Protagonist Therapeutics and Takeda review blood cancer data, and more.

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The ...

According to the latest study from BCC Research, the "Cancer Immunotherapy: Technologies and Global Markets" is expected to ...

AstraZeneca Pill Cut Risk of Breast Cancer Death, Study Finds. Doctors used a blood test called a ‘liquid biopsy’ to make early treatment decisions for the first time. BY REUTERS.

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.